Case Reports
3 October 2024

Bullous pemphigoid with secondary acquired reactive perforating collagenosis: a challenging clinical case report

Authors

Bullous pemphigoid (BP) is a common autoimmune blistering disorder with unknown aetiology. During the last decades, its association with various common comorbidities, including cardiovascular, metabolic, neuropsychiatric, and neoplastic disorders, has been established. However, in recent years, an increasing number of BP cases have also been reported in association with rarer diseases, including acquired reactive perforating collagenosis (ARPC). Patients with coexisting BP and ARPC have been reported to share common clinical features, including metabolic comorbidities, e.g., diabetes mellitus (DM). As the evolution from ARPC cutaneous involvement to classic BP lesions has been more frequently described, it has been suggested that it may represent a new clinical variant of BP with a specific pathogenetic background. Here is reported a challenging case in which a typical onset of BP was later followed by the eruption of atypical ARPC lesions in a patient with multiple non-compensated metabolic and cardiovascular comorbidities.

Altmetrics

Downloads

Citations

Mehregan A, Schwartz OD, Livingood CS. Reactive Perforating Collagenosis. Arch Dermatol 1967;96:277-82.
Rapini R, Herbert AA, Drucker CR. Acquired perforating dermatosis. Evidence for combined transepidermal elimination of both collagen and elastic fibers. Arch Dermatol 1989;125:1074-8.
Karpouzis A, Giatromanolaki A, Sivridis E, Kouskoukis C. Acquired reactive perforating collagenosis: current status. J Dermatol 2010;37:585-92.
Patel S, Ahsanuddin S, Cadwell JB, Lambert WC. The impact of diabetes mellitus on medical complication and mortality rates among inpatients with bullous pemphigoid. Ir J Med Sci 2022;191:1669-75.
Borradori L, Van Beek N, Feliciani C, et al. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol 2022;36:1689-704.
Theodoridis A, Makrantonaki E, Zouboulis C. Malignant atrophic papulosis (Köhlmeier-Degos disease) - A review. Orphanet J Rare Dis 2013;8:10.
Ormerod E, Atwan A, Intzedy L, Stone N. Dermoscopy features of acquired reactive perforating collagenosis: a case series. Dermatol Pract Concept 2018;8:303-5.
Geiss Steiner J, Trüeb RM, Kerl K, et al. Ecthyma-gangrenosum-like bullous pemphigoid. Dermatol 2010;221:142-8.
Tani S, Ishii N, Hashimoto T, Tsujioka K. Bullous pemphigoid arising in a patient with acquired perforating dermatosis. Clin Exp Dermatol 2017;42:406-9.
Nomura H, Mukai M, Niimi Y, et al. Coexistence of acquired perforating dermatosis and bullous pemphigoid: three cases. Eur J Dermatol 2017;27:192-3.
Maki N, Nishie W, Takazawa M, et al. Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid in a patient with acquired reactive perforating collagenosis. J Dermatol 2018;45:600-2.
Schauer F, Kern JS, Virtic O, et al. A new clinical variant of acquired reactive perforating dermatosis-like bullous pemphigoid. Br J Dermatol 2019;180:231-2.
Gambichler T, Espey B, Doerler M, Stranzenbach R. Dipeptidyl peptidase-4 inhibitor induced bullous pemphigoid complicated by acquired reactive perforating dermatosis. Actas Dermosifiliogr 2022;113:914-5.
Salemme A, Fania L, Scarabello A, et al. Gliptin-associated bullous pemphigoid shows peculiar features of anti-BP180 and -BP230 humoral response: Results of a multicenter study. J Am Acad Dermatol 2022;87:56-63.
Schmidt E, Spindler V, Eming R, et al. Meeting report of the pathogenesis of pemphigus and pemphigoid meeting in Munich, September 2016. J Invest Dermatol 2017;137:1199-203.
García-Malinis AJ, Del Valle Sánchez E, Sánchez-Salas MP, et al. Acquired perforating dermatosis: clinicopathological study of 31 cases, emphasizing pathogenesis and treatment. J Eur Acad Dermatol Venereol 2017;31:1757-63.
Kim S, Kim M, Lee JH, et al. A clinicopathologic study of thirty cases of acquired perforating dermatosis in Korea. Ann Dermatol 2014;26:162.
Bellinato F, Maurelli M, Gisondi P, Girolomoni G. Acquired perforating dermatoses show increased levels of cutaneous advanced glycation end‐products. Clin Exp Dermatol 2021;47:80-5.

How to Cite



Bullous pemphigoid with secondary acquired reactive perforating collagenosis: a challenging clinical case report. (2024). Dermatology Reports, 17(1). https://doi.org/10.4081/dr.2024.10087